Related Experiment Videos

Pharmacotherapy of cholestatic liver diseases

Gustav Paumgartner1

  • 1Department of Medicine II, Klinikum Grosshadern, University of Munich, Munich, Germany. gustav.paumgartner@med.uni-muenchen.de

Journal of Digestive Diseases
|June 29, 2010
PubMed

Insights

New pharmacotherapies for cholestatic liver diseases focus on reducing bile acid buildup. Ursodeoxycholic acid is key for primary biliary cirrhosis, with new drugs showing promise.

Area of Science:

  • Hepatology and Gastroenterology
  • Molecular Medicine
  • Pharmacology

Background:

  • Cholestatic liver diseases are characterized by impaired bile flow and hepatocellular retention of toxic bile acids.
  • Understanding molecular mechanisms of bile formation and cholestasis is crucial for developing effective pharmacotherapies.
  • Primary biliary cirrhosis (PBC) involves biliary epithelium injury, necessitating protection against hydrophobic bile acids.

Purpose of the Study:

  • To explore new pharmacotherapeutic strategies for cholestatic liver diseases.
  • To identify therapeutic targets for reducing hepatocellular bile acid retention and toxicity.
  • To evaluate the role of ursodeoxycholic acid and novel drug candidates in managing cholestasis.

Main Methods:

  • Review of molecular mechanisms of bile formation and cholestasis.
  • Analysis of drug-induced stimulation of hepatocellular secretion and metabolism.
  • Evaluation of protective effects on cholangiocytes and inhibition of apoptosis.

Main Results:

  • Pharmacotherapies aim to reduce hepatocellular retention of bile acids via enhanced secretion or metabolism.
  • Ursodeoxycholic acid (UDCA) protects biliary epithelium, stimulates hepatobiliary secretion, and inhibits apoptosis.
  • New agents like 6-ethyl-chenodeoxycholic acid and 24-nor-ursodeoxycholic acid are under investigation.

Conclusions:

  • Targeting hepatocellular retention and bile acid toxicity is central to managing cholestatic liver diseases.
  • Ursodeoxycholic acid is a cornerstone therapy for PBC and beneficial in other cholestatic conditions.
  • Emerging drugs offer potential for improved treatment of cholestatic liver diseases.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...